ESVM guidelines - the diagnosis and management of Raynaud's phenomenon.

Raynaud’s; hand arm vibration; systemic sclerosis; vasospasm; Consensus; Humans; Predictive Value of Tests; Raynaud Disease/classification; Raynaud Disease/diagnosis; Raynaud Disease/epidemiology; Raynaud Disease/therapy; Risk Factors; Terminology as Topic; Treatment Outcome; Raynaud Disease; Cardiology and Cardiovascular Medicine

Abstract :

[en] Regarding the clinical diagnosis of Raynaud's phenomenon and its associated conditions, investigations and treatment are substantial, and yet no international consensus has been published regarding the medical management of patients presenting with this condition. Most knowledge on this topic derives from epidemiological surveys and observational studies; few randomized studies are available, almost all relating to drug treatment, and thus these guidelines were developed as an expert consensus document to aid in the diagnosis and management of Raynaud's phenomenon. This consensus document starts with a clarification about the definition and terminology of Raynaud's phenomenon and covers the differential and aetiological diagnoses as well as the symptomatic treatment.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Belch, Jill; 1 University of Dundee School of Medicine, Dundee, United Kingdom

Carlizza, Anita; 2 Azienda Ospedaliera S.Giovanni-Addolorata, Rome, Italy

Carpentier, Patrick H; 3 Grenoble University Hospital, Grenoble, France

Constans, Joel; 4 Hopital St Andre, Bordeaux, France

Khan, Faisel; 1 University of Dundee School of Medicine, Dundee, United Kingdom

Wautrecht, Jean-Claude; 5 Cliniques universitaires de Bruxelles, Brussels, Belgium

Visona, Adriana; 6 Angiology Unit, Azienda ULSS 2, Marca Trevigiana, Treviso, Italy

Heiss, Christian; 7 Department of Cardiology, Pulmonology and Vascular Medicine, Düsseldorf, Germany

Brodeman, Marianne; 8 Division of Angiology, Medical University, Graz, Austria

Pécsvárady, Zsolt; 9 Head of 2nd Dept. of Internal Medicine, Vascular Center, Flor Ferenc Teaching Hospital, Kistarcsa, Hungary

More authors (16 more)

Language :

English

Title :

ESVM guidelines - the diagnosis and management of Raynaud's phenomenon.

Publication date :

October 2017

Journal title :

VASA. Zeitschrift für Gefasskrankheiten

ISSN :

0301-1526

Publisher :

Verlag Hans Huber AG, Switzerland

Volume :

Issue :

Pages :

413 - 423

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://econtent.hogrefe.com/doi/pdf/10.1024/0301-1526/a000661

Available on ORBi :

since 20 May 2025

Statistics

Number of views

37 (0 by ULiège)

Number of downloads

33 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

118

Bibliography

Maricq HR, Carpentier PH, Weinrich MC, et al. Geographic variation in the prevalence of Raynaud’s phenomenon: a 5 region comparison. J Rheumatol 1997; 24: 879-89.
Baines C, Kumar P, Belch JJF. Raynaud’s Phenomenon: Connective Tissue Disorders: Systemic Sclerosis. In Rheumatology. MC Hochberg, AJ Silman, JS Smolen, Weinblatt ME, Weisman MH (Eds). Rheumatology 6th Edn. Elsevier Limited. 2013.
European Society of Cardiology. Recommendations for Guidelines Production. A Document for Task Force Members. Internet: (Accessed 12th June 2016) https://www.escardio.org/static_file/Escardio/Guidelines/ESC%20Guidelines%20 for%20Guidelines%20Update%202010.pdf.
Raynaud M. On local asphyxia and symmetrical gangrene of the extremities, 1864. London: The New Sydenham Society; 1888.
Maverakis E, Patel F, Kronenberg DG, et al. International consensus criteria for the diagnosis of Raynaud’s phenomenon. J Autoimmun 2014;48-49: 60-5.
Belch JJF, Land D, Park RHR, et al. Decreased oesophageal blood fl ow in patients with Raynaud’s phenomenon. Brit J Rheum 1988; 27 (6): 426-30.
Classification Criteria for Systemic Sclerosis: An ACR-EULAR Collaborative Initiative. Arthritis Rheum. 2013 Nov; 65(11): 2737-47.
Allegra C, Carlizza A, Pollari G, et al. Acrocyanosis: experimental fi ndings. In Advances in Vascular Pathology 1989. Strano A, Novo S (Eds). Elsevier Science Publ. 1989.
Gibbs MB, English JC, Zirwas MJ. Livedo reticularis: an update. J Am Acad Dermatol 2005;52:1009-19.
Prakash S, Weisman MH. Idiopathic chilblains. Am J Med 2009; 122:1152-55.
Spittell JA, Jr. Vascular Syndromes related to environmental temperature. In: Peripheral Vascular Diseases, Fifth Edition, 1980: 585-605. Ed JL Juergens, JA Spittell Jr, JF Fairbairn.W.B. Saunders Company. ISBN 0-7216-5229-8.
Carpentier PH, Maricq HR, Biro C, et al. Paroxysmal fi nger haematoma - a benign acrosyndrome occurring in middle-aged women. Vasa 2016; 45: 57-62.
Imray C, Grieve A, Dhillon S. Cold damage to the extremities: frostbite and non-freezing cold injuries. Postgrad Med J 2008;85:481-88.
Nihtyanova SI, Tang EC, Coghlan GJ, et al. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. Q J Med 2010; 103:109-15.
Soyfoo MS, Goubella A, Cogan E, et al. Clinical signifi cance of cryofi brinogenemia: possible pathophysiological link with Raynaud’s phenomenon. J Rheumatol 2012; 39(1):119-24.
Pistorius MA, Carpentier PH for the working group on Microcirculation of the SFMV. Minimal etiological work-up for Raynaud phenomenon. A consensus report. J Mal Vasc 2012; 37:207-12.
Pavlov-Dolijanovic S, Damjanov NS, Stojanovic RM, et al. Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a follow-up study of 3,029 patients with primary Raynaud’s phenomenon. Rheum Int 2012; 32(10):3039-45.
Carlizza A, Allegra C. Clinical and laboratory evaluation of Raynaud’s phenomenon. Int J Microcirc 1994; 14 (S1):100.
Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud’s phenomenon: a meta-analysis. Rheumatology 2005; 44 (2):145-50.
Ennis H, Hughes M, Anderson ME, et al. Calcium channel blockers for primary Raynaud’s phenomenon. Cochrane Database of Systematic Reviews 2016. DOI: 10.1002/14651858.CD002069.pub5.
Rhedda A, McCans J, Willan AR, et al. A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud’s phenomenon. J Rheumatol 1985;12:724-7.
Stewart M, Morling JR. Oral vasodilators for primary Raynaud’s phenomenon. Cochrane Database of Systematic Reviews 2012, Issue 7.
Hughes M, Ong VH, Anderson ME, et al. Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis. Rheumatology 2015; 54: 2015-24.
Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fl uoxetine. Rheumatology 2001; 40 (9): 1038-43.
Roustit M, Blaise S, Allanore Y, et al. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud’s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis 2013;72(10):1699.
Shenoy PD, Kumar S, Jha LK, et al. Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatol 2010, 49: 2420-8.
Herrick AL, Van den Hoogen F, Gabrielli A, et al. Modified- Release sildenafi l reduces Raynaud’s phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 2011, 63: 775-82.
Caglayan E, Axmann S, Hellmich M, et al. Vardenafil for the treatment of Raynaud phenomenon: a randomized, doubleblind, placebo-controlled crossover study. Arch Intern Med 2012, 172: 1182-4.
Lee EY, Park JK, Lee W, et al. Head-to-head comparison of udenafilvs amlodipine in the treatment of secondary Raynaud’s phenomenon: a double-blind, randomized, cross-over study. Rheumatol 2014; 53: 658-64.
Chung L, Shapiro L, Fiorentino D, et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud’s phenomenon. Arthritis Rheum 2009;60:870-7.
Yardumian DA, Isenberg DA, Rustin M, et al. Successful treatment of Raynaud’s syndrome with iloprost, a chemically stable prostacyclin analogue. Br J Rheumatol 1988;27:220-6.
Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized controlled trial. Ann Intern Med 2000;132:425-34.
Belch JJF, Capell HA, Cooke ED, et al. Oral iloprost as a treatment for Raynaud’s syndrome: A double-blind multicentre placebo controlled study. Ann Rheum Dis 1995; 54 (3): 197-200.
Pope J, Fenlon D, Thompson A, S et al. Iloprost and cicaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database of Systematic Reviews 1998, Issue 2.
Seibold JR, Wigley FM, Schiopu E, et al. Digital ulcers in SSc treated with oral treprostinil: a randomized, double-blind, placebo- controlled study with open-label follow-up. J Scleroderma Rel Disorders 2017; 2: 42-9.
Herrick A, Muir L. Raynaud’s phenomenon (secondary). Clinical Evidence (Online). BMJ Publishing Group Ltd 2015.
Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud‘s phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallelgroup, controlled trial. Arthritis Rheum 1999;42(12): 2646-55.
Korn JH, Mayes M, Matucci-Cerinic M, et al. Digital ulcers in systemic sclerosis. Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50:3985-93.
Matucci-Cerinic M, Denton CP, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011;70:32-8.
Muir L. Surgical management. In: Raynaud’s Phenomenon: A Guide to Pathogenesis and Treatment. Edited by FM Wigley, AL Herrick, NA Flavahan (editors). New York: Springer; 2015: 361-72.
Merritt WH. Role and rationale for extended periarterial sympathectomy in the management of severe Raynaud syndrome: techniques and results. Hand Clinics 2015; 31: 101-20.
Poredos P. Raynaud‘s syndrome - a neglected disease. Int Angiol 2016;35(2):117-21.